Form 4: Protagonist Therapeutics Director Bryan Giraudo Reports Stock and Option Grants

Director Bryan Giraudo reports receiving restricted stock units and stock options from Protagonist Therapeutics.

Summary

• On January 2, 2025, Bryan Giraudo, a director of Protagonist Therapeutics, Inc., reported transactions involving the company's stock.
• Giraudo acquired 5,130 shares of common stock through a grant of restricted stock units.
• These restricted stock units will vest in full on January 15, 2026, contingent upon continued service to the issuer.
• Giraudo also acquired options to purchase 6,584 shares of common stock at an exercise price of $38.98.
• The stock options vest in 12 equal monthly installments following January 2, 2025, also subject to continued service.
• Following these transactions, Giraudo directly owns 15,130 shares of common stock and indirectly owns 8,000 shares through the Bryan & Courtney Giraudo Trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock and option grants, which is neither particularly positive nor negative.

Positives

• The grant of restricted stock units and stock options aligns the director's interests with the company's long-term performance.
• The vesting schedules incentivize continued service to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the granted securities.

Industry Context

Form 4 filings are standard disclosures for company insiders and provide transparency into their transactions involving the company's securities. This is a routine part of corporate governance.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of compensation for directors in publicly traded biotechnology companies.
• The vesting schedules are typical, designed to retain talent and align interests with long-term shareholder value.
• Comparable companies such as BioCryst Pharmaceuticals, Inc. and Vertex Pharmaceuticals Incorporated also utilize stock options and RSUs as part of their director compensation packages.

Stakeholder Impact

• The grants could have a minor dilutive effect on existing shareholders.
• The grants incentivize the director to work towards increasing shareholder value.

Key Dates